Tech firm moves HQ within Plano, looks to hire 100 new employees

While Allied BioScience isn’t moving its headquarters very far, the biotech company has big plans for its new site.

The Plano-based firm, which focuses on novel antimicrobial coatings designed to reduce infection and illness across public spaces, is moving from its current location in Plano to new offices in the One Legacy Circle building, owned by Franklin Street Properties, in the city’s Legacy business park.

Allied first moved its HQ to Plano in 2015 from Uptown Dallas, about 10 years after it launched. According to the company’s website, it also has an office in New South Wales, Australia.

“The new space will provide room for the company's growing team… to support significant sales increases,” a spokesperson for the company said via email.

The new move, brokered by JLL, will double the company’s current footprint in Plano to more than 28,000 square feet. Allied is also planning to relocate its R&D labs to a new space within the city in the near future, though the location of that site is still being finalized, the spokesperson said.

Like many health care-related companies, Allied has been seeing an increased demand. In April, it announced closing a Series B-1 funding round from Plano- and Florida-based investment firm Lydia Partners. While the amount was undisclosed, a previous filing with the SEC showed the company was seeking about $6.2 million prior to the announcement. Then, in August, the company received a public health emergency exemption waiver to use its SurfaceWise2 antimicrobial product to fight the spread of COVID-19.

To capture that continued growth, Allied, which had about 50 employees in June, is looking to more than double its headcount with plans to hire more than 100 people across all departments, especially as it expects more EPA authorizations this quarter, the spokesperson said. The company currently has positions in sales, accounting and R&D posted on its website.

In the coming months, Allied is also planning to launch new products beyond surface coatings.

"For well over a decade, Allied BioScience has remained committed to fighting the global burden of infectious disease, and the past year has been our most exciting to date as we worked… to fight SARS-CoV-2," said Michael Ruley, CEO Allied BioScience, in a statement. "This year, we expect tremendous, continued growth.”